Camp4 Therapeutics Secures $97.5M in Funding, Extends Cash Runway to 2028, Advances Lead Program

summarizeSummary

Camp4 Therapeutics announced full-year 2025 financial results, highlighted by securing $97.5 million in new capital through a GSK collaboration, private placement, and underwritten offering, extending its cash runway into 2028.

check_boxKey Events

• Secured $97.5 Million in New Capital

  The company raised $50 million from an upfront private placement and $30 million from an underwritten offering, in addition to a $17.5 million upfront payment from a new collaboration with GSK.

• Cash Runway Extended to 2028

  With $109.5 million in cash and equivalents as of December 31, 2025, the company projects its current funds will be sufficient to finance planned activities into 2028.

• Strategic Collaboration with GSK

  Entered a research, collaboration, and license agreement with GSK, receiving a $17.5 million upfront payment and potential for up to $440 million in development and commercial milestones, plus tiered royalties.

• Lead Program Progressing to Clinic

  GLP toxicology studies for CMP-002 (SYNGAP1 program) are ongoing, with initiation of a global Phase 1/2 clinical trial expected as early as the second half of 2026.

auto_awesomeAnalysis

Camp4 Therapeutics has significantly strengthened its financial position and strategic outlook. The company secured a total of $97.5 million in new capital, comprising a $17.5 million upfront payment from a strategic collaboration with GSK, a $50 million private placement, and a $30 million underwritten offering. This substantial capital infusion, representing approximately 41% of its current market capitalization, is critical for a clinical-stage biotech and extends its cash runway into 2028. While the equity raises are dilutive, they ensure the company's ability to fund operations and advance its lead SYNGAP1 program, which is progressing towards a Phase 1/2 clinical trial in the second half of 2026. The GSK collaboration also provides significant external validation and potential for substantial future milestones.